From GlobeNewswire: 2025-03-03 07:00:00

ArriVent BioPharma reported strong clinical data for firmonertinib in first-line NSCLC EGFR PACC mutations. Achieved target enrollment for Phase 3 study in EGFR exon 20 insertion mutations. Selected next-generation ADC candidate ARR-002 for IND enabling studies. Financially, $266.5 million in cash as of December 31, 2024, with a net loss of $80.5 million in 2024.

Chairman Bing Yao highlighted successful firmonertinib clinical programs and expanded ADC portfolio. Achieved target enrollment for Phase 3 study and planned update for first-line NSCLC with EGFR PACC mutations. Selected ARR-002 as next-gen ADC candidate, focusing on near-term catalysts for impactful year ahead.

Firmonertinib demonstrated robust anti-tumor activity in NSCLC patients with EGFR PACC mutations. Preclinical data at AACR showed broad activity against uncommon mutations. Initiating Phase 1b combination study with SHP2 allosteric inhibitor. Cash, cash equivalents, and investments of $266.5 million as of December 31, 2024.

Pipeline expansion includes adding ARR-217 from Lepu Biopharma and selecting ARR-002 as next-gen ADC candidate. Collaboration with Alphamab for novel ADCs. Upcoming milestones include data update for firmonertinib in EGFR PACC mutations and first IND filing for ARR-217 in 2025. Top-line pivotal Phase 3 data expected in 2025.

Financially, ArriVent had cash and equivalents of $266.5 million as of December 31, 2024, with net loss of $80.5 million in 2024. Research and development expenses increased due to firmonertinib clinical activities. General and administrative expenses rose to support infrastructure expansion as a public company.



Read more at GlobeNewswire:: ArriVent BioPharma Reports Full Year 2024 Financial